Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine with or without sabatolimab in higher-risk MDS or CMML-2
2019-002089-11Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) comparing Sabatolimab + azacitidine with Placebo + azacitidine (2 arms). Primary endpoint: Overall survival. Started Jan 2020; status: completed.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2019-002089-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002089-11.